NCT02801071

L-Citrulline in Patients With Post-Polio Syndrome

Completed Phase 3 Last updated 23 January 2019

What this trial tests

Phase 3 trial testing 15g L-citrulline daily p.o. in Post-Polio Syndrome in 30 participants. Completed in 5 October 2018.

Timeline

14 June 2016

Primary endpoint
15 August 2017

5 October 2018

Quick facts

Lead sponsor	Dirk Fischer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	14 June 2016
Primary completion	15 August 2017
Estimated completion	5 October 2018
Sites	1 location across Switzerland

Drugs / interventions tested

• 15g L-citrulline daily p.o. — full drug profile →
• Placebo

Conditions studied

• Post-Polio Syndrome — all drugs for Post-Polio Syndrome →

Sponsor

Dirk Fischer — full company profile →

Who can join

18 and older, any sex, with Post-Polio Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to show that the intake of L-citrulline improves muscle function in patients with Post-Polio Syndrome (PPS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial.
   Schmidt S, Gocheva V, Zumbrunn T, Rubino-Nacht D, et al · · 2017 · cited 7× · PMID 28274276 · DOI 10.1186/s13063-017-1829-3
2. Health-related quality of life, self-reported impairments and activities of daily living in relation to muscle function in post-polio syndrome.
   Gocheva V, Hafner P, Orsini AL, Schmidt S, et al · · 2020 · cited 2× · PMID 32676980 · DOI 10.1186/s41687-020-00226-5